Conference Highlights ADA
San Diego, CA—During the 2011 Scientific Sessions of the American Diabetes Association (ADA), American Health & Drug Benefits interviewed Robert Henry, MD, ADA President, Medicine & Science, and Chief, Endocrinology Division, San Diego Veterans Affairs Healthcare System, and Professor of Medicine in Residence at the University of California, San Diego.
Type 2 Diabetes Treatment in Patients with CKD Should Conform to NKF Guidelines for Better Outcomes, Lower Costs
San Diego, CA—Patients with type 2 diabetes and chronic kidney disease (CKD) are not being appropriately treated for their diabetes, according to a study based on a large electronic database from an integrated health system, presented at the 2011 Scientific Sessions of the American Diabetes Association.
San Diego, CA—Blood glucose testing constitutes more than 20% of US pharmacy costs in patients taking insulin, investigators from the IMS Consulting Group, Alexandria, VA, found in a study presented at the 2011 Scientific Sessions of the American Diabetes Association.
“New insulin regimens with simpler, user-friendly dosing options and simpler titration are warranted in order to enable relevant cost-savings,” the researchers stated.
San Diego, CA—Diabetes education can play a crucial role in optimizing the management of patients with type 2 diabetes, resulting in significant cost-savings when trained nurse educators provide education and continued support in the context of a team approach and case management. This was a key message of the Outstanding Educator in Diabetes Education Award lecture on “The Long and Winding Road—My Journey in Diabetes Education,” given by Linda M.
San Diego, CA—Lifestyle intervention is cost-effective and metformin therapy is cost-saving in the prevention of type 2 diabetes in persons at high risk for developing the disease, said William H. Herman, MD, MPH, Professor of Medicine and Epidemiology, University of Michigan, Ann Arbor, at the 71st Scientific Sessions of the American Diabetes Association. These economic findings were derived from a 10-year cost analysis as a follow-up to the landmark Diabetes Prevention Program (DPP).
San Diego, CA—Linagliptin—a dipeptidyl peptidase (DPP)-4 inhibitor—was as effective as glimepiride in lowering blood glucose in patients with type 2 diabetes, and the newer drug demonstrated some safety advantages over glimepiride. It was associated with a lower incidence of hypoglycemia, fewer cardiovascular events, and weight loss instead of weight gain. These were 2-year data from an industry-sponsored, randomized, double-blind, noninferiority study comparing linagliptin with glimepiride in patients with type 2 diabetes inadequately controlled with metformin.
Initiation of Therapy with a Sulfonylurea Increased Risk of Cardiovascular Events versus Metformin in Older Adults with Type 2 Diabetes
San Diego, CA—Initiating treatment with a sulfonylurea was associated with a 33% greater likelihood of sustaining a cardiovascular event and a shorter time to sustaining a cardiovascular event compared with metformin in older adults with type 2 diabetes, according to a retrospective analysis presented at the 2011 Scientific Sessions of the American Diabetes Association. Older age and being male were associated with an increase in cardiovascular events.
San Diego, CA—Adding saxagliptin to metformin instead of increasing the dose of metformin significantly improves levels of hemoglobin (Hb)A1c, fasting plasma glucose, and postprandial glucose in patients with type 2 diabetes who demonstrate inadequate glycemic control despite receiving a stable dose of metformin, according to the results of a randomized, open-label study presentedat the 71st Scientific Sessions of the American Diabetes Association.
San Diego, CA—The investigational once-weekly form of exenatide (Bydureon) was equally effective to metformin, slightly less effective than pioglitazone, and significantly superior to sitagliptin in achieving glycemic control in drug-naïve patients with type 2 diabetes not adequately controlled with diet and exercise in the 26-week DURATION-4 study.
San Diego, CA—Patients with type 2 diabetes who only take oral antidiabetic drugs report a more favorable treatment experience than those taking insulin, said Richard R. Rubin, MD, Professor of Medicine and Pediatrics, Johns Hopkins University, Baltimore, MD, at the 2011 Scientific Sessions of the American Diabetes Association.
Page 1 of 3
Results 1 - 10 of 22
Results 1 - 10 of 22